<div id="readability-page-1"><p>In a report released on January 28, Pablo de Renteria from Kepler Capital  maintained a Buy rating on Lonza Group Ltd, with a price target of <span id="expert-recommendation-target">CHF670.00</span>.</p><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>According to TipRanks, de Renteria is an analyst with an average return of <span>-3.5%</span> and a 42.00% success rate. de Renteria covers the Healthcare sector, focusing on stocks such as Laboratorios Farmaceuticos Rovi, Almirall, and Lonza Group Ltd.</p> <p>In addition to Kepler Capital , Lonza Group Ltd also received a Buy from Goldman Sachs’s James Quigley in a report issued yesterday. However, on January 28, TipRanks – xAI upgraded Lonza Group Ltd (Six Swiss: LONN) to a Hold.</p></div>

LZAGY

SBIO

<p>Lonza Group Ltd (LONN) has received a Buy rating from Kepler Capital, with a price target of CHF670.00, according to analyst Pablo de Renteria. He has an average return of -3.5% and a 42% success rate. Additionally, Goldman Sachs analyst James Quigley also issued a Buy rating for Lonza. However, TipRanks upgraded the stock to a Hold on the same day.</p>

Tip Ranks

Lonza

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Lonza Group Ltd (LONN) Receives a Buy from Kepler Capital